Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR)

Authors: Alobid, Isam, Andrianakis, Alexandros, Hellings, Peter W., Hopkins, Claire, Hox, Valérie, Kjeldsen, Anette, Laulajainen-Hongisto, Anu, Lund, Valerie, Van Gerven, Laura, Seys, Sven F. ^{a, ∗}, Schneider, Sven ^b, de Kinderen, Joost ^a, Reitsma, Sietze ^c, Cavaliere, Carlo ^d, Tomazic, Peter-Valentin ^e, Morgenstern, Christina ^b, Mortuaire, Geoffrey ^f, Wagenmann, Martin ^g, Bettio, Giulia ^a, Ciofalo, Andrea ^d, Diamant, Zuzana ^{h, i, j}, Eckl-Dorna, Julia ^b, Fokkens, Wytske J. ^c, Holzmeister, Clemens ^e, Mariën, Gert ^a, Masieri, Simonetta ^k, Otten, Josje ^c, Scheckenbach, Kathrin ^g, Tu, Aldine ^b, Bachert, Claus ^{l, m}

Source: In The Journal of Allergy and Clinical Immunology February 2025 155(2):451-460

Two‐year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months

Authors: Lans, Rik Johannes Leonardus, Otten, Josje Janna, Adriaensen, Gwijde Flavius Jacobus Petrus Maria, Hoven, Dinand Rienk, Benoist, Linda Berendina, Fokkens, Wytske Johanna, Reitsma, Sietze

Source: Allergy. 78(10):2684-2697

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100194503879.0x000001&indx=1&recIds=ETOCvdc_100194503879.0x000001

Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making

Authors: Otten, Josje, van der Lans, Rik, de Corso, Eugenio, Dziadziulia, kanstantsin, Hilvering, Bart, Weersink, Els, Bonini, Matteo, Hagemann, Jan, Thaitrakool, Wanrawee, Montuori, Claudio, Klimek, Ludger, Reitsma, Sietze, Fokkens, Wytske

Source: Expert review of clinical immunology. 19(8):1041-1049

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100187877141.0x000001&indx=1&recIds=ETOCvdc_100187877141.0x000001

Diagnosis, treatment and prognosis of otomastoiditis induced by Fusobacterium necrophorum: A retrospective multicentre cohort study

Authors: Thevis, Madelon, Leow, Theresa Y.S., Bekkers, Stijn, Otten, Josje, Waterval, Jerome J., Derks, Jolanda, Buil, Jochem B., Kunst, Henricus P.M., Jansen, Thijs T.G.

Source: In Anaerobe August 2022 76

The association between radiological spreading pattern and clinical outcomes in necrotizing external otitis

Authors: van der Meer, W. Leentje, Bayoumy, Ahmed B., Otten, Josje J., Waterval, Jerome J., Kunst, Henricus P.M., Postma, Alida A.

Source: In Journal of Otology July 2022 17(3):156-163

Olfactory Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Effect of Treatment with Emphasis on Biological Therapy.

Authors: Otten, Josje Janna, Fokkens, Wytske Johanna, Reitsma, Sietze

Source: Current Allergy & Asthma Reports; 2025, Vol. 25 Issue 1, p1-11, 11p

Almost Half of the Dupilumab‐Treated Patients With Severe Chronic Rhinosinusitis With Nasal Polyps Achieve Remission in One Year.

Authors: Otten, Josje J.¹ (AUTHOR), Elzinga, Hester E.¹ (AUTHOR), van der Lans, Rik J. L.¹ (AUTHOR), Fokkens, Wytske J.¹ (AUTHOR), Reitsma, Sietze¹ (AUTHOR) s.reitsma@amsterdamumc.nl, Cornet, M. E.¹ (AUTHOR), Rinia, A. B.¹ (AUTHOR), Kleiss, I. J.¹ (AUTHOR), Krebbers, I.¹ (AUTHOR), Adriaensen, G. F. J. P. M.¹ (AUTHOR), Benoist, L. B. L.¹ (AUTHOR), Hoven, D. R.¹ (AUTHOR), Timmer, F. C. A.¹ (AUTHOR)

Source: Allergy. Apr2025, Vol. 80 Issue 4, p1166-1168. 3p.

Subject Terms: *DUPILUMAB, *DISEASE remission, *SINUSITIS, *TREATMENT effectiveness, *BIOTHERAPY, *NASAL polyps

More than half of chronic rhinosinusitis with nasal polyps (CRSwNP) patients treated with dupilumab experience early and fast olfactory improvement within 28 days.

Authors: Otten, Josje Janna¹ (AUTHOR) j.j.otten@amsterdamumc.nl, van der Lans, Rik Johannes Leonardus¹ (AUTHOR), Elzinga, Hester Beatrice Emilie¹ (AUTHOR), Adriaensen, Gwijde Flavius Jacobus Petrus Maria¹ (AUTHOR), Benoist, Linda Berendina Laurentia¹ (AUTHOR), Hoven, Rienk D.¹ (AUTHOR), Seys, Sven² (AUTHOR), Fokkens, Wytske Johanna¹ (AUTHOR), Reitsma, Sietze¹ (AUTHOR)

Source: Allergy. Nov2024, Vol. 79 Issue 11, p3166-3168. 3p.

Subject Terms: *WILCOXON signed-rank test, *INNATE lymphoid cells, *PATIENT experience, *DATA libraries, *SMELL disorders

Steroid responsiveness predicts olfactory function recovery in dupilumab treated CRSwNP.

Authors: Otten, Josje J., van der Lans, Rik J. L., Benoist, Linda B., Adriaensen, Gwijde F. J. P. M., Hoven, Rienk D., Verkest, Valerie, Fokkens, Wytske J., Reitsma, Sietze

Source: Rhinology; 2024, Vol. 62 Issue 4, p403-409, 7p

Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps.

Authors: Kemp, Pieter, van der Lans, Rik J. L., Otten, Josje J., Adriaensen, Gwijde F. J. P. M., Benoist, Linda B. L., Cornet, Marjolein E., Hoven, D. Rienk, Rinia, Bas, Verkest, Valerie, Fokkens, Wytske J., Reitsma, Sietze

Source: Rhinology; 2024, Vol. 62 Issue 2, p202-207, 6p

Eosinophils are the dominant type2 marker for the current indication of biological treatment in severe uncontrolled chronic rhinosinusitis with nasal polyps.

Authors: van der Lans, Rik J. L., Otten, Josje J., Adriaensen, Gwijde F. J. P. M., Benoist, Linda B. L., Cornet, Marjolein E., Hoven, D. Rienk, Rinia, Albert B., Fokkens, Wytske J., Reitsma, Sietze

Source: Rhinology; 2024, Vol. 62 Issue 3, p383-385, 3p

Two‐year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months.

Authors: van der Lans, Rik Johannes Leonardus¹ (AUTHOR) r.vanderlans@amsterdamumc.nl, Otten, Josje Janna¹ (AUTHOR), Adriaensen, Gwijde Flavius Jacobus Petrus Maria¹ (AUTHOR), Hoven, Dinand Rienk¹ (AUTHOR), Benoist, Linda Berendina¹ (AUTHOR), Fokkens, Wytske Johanna¹ (AUTHOR), Reitsma, Sietze¹ (AUTHOR)

Source: Allergy. Oct2023, Vol. 78 Issue 10, p2684-2697. 14p.

Subject Terms: *DUPILUMAB, *NASAL polyps, *CONDITIONED response, *NASAL tumors, *TREATMENT effectiveness, *ONE-way analysis of variance

Characteristics and Clinical Management Strategy of Petrous Apex Cholesterol Granulomas.

Authors: de Bock, Sanne, Szweryn, Walter, Jansen, Thijs, Otten, Josje, Mulder, Jef, Waterval, Jérôme, Temel, Yasin, Bekkers, Stijn, Kunst, Henricus

Source: Cancers; Feb2023, Vol. 15 Issue 4, p1313, 11p

Subject Terms: GRANULOMA, PETROUS bone, TIME, CONVALESCENCE, SURGICAL complications, HEALTH outcome assessment, TREATMENT effectiveness, CASE studies, MEDICAL records, DESCRIPTIVE statistics, ADVERSE health care events, DATA analysis software, CHOLESTEROL, EVALUATION, SYMPTOMS